论文部分内容阅读
目的观察化学治疗(化疗)加用甲羟孕酮(MPA)治疗侵蚀性葡萄胎及绒毛膜癌(绒癌)患者的临床疗效。方法侵蚀性葡萄胎及绒癌患者25例,进行自身对照。按常规方法应用氟尿嘧啶、更生霉素8 d疗程,第1疗程不用MPA为对照组,第2疗程开始前1周加用MPA 200 mg.d-1口服为试验组;远期10例Ⅲ期为远期组(未用MPA),近期10例Ⅲ期为近期组(加用MPA)。观察化疗前后两组食欲、恶心、呕吐、口腔溃疡等情况;两组化疗前后白细胞变化及细胞因子白细胞介素-6(IL-6)的变化;比较近期组和远期组化疗疗程数及肺转移结局。结果试验组食欲、恶心、呕吐、口腔溃疡等明显好于对照组(P<0.01);试验组化疗前后白细胞无明显变化(P>0.05),对照组化疗后白细胞明显下降(P<0.01);试验组细胞因子IL-6明显低于对照组(P<0.01);近期组化疗疗程数明显低于远期组,肺转移灶消失时间短于远期组(P<0.01)。结论MPA降低了细胞因子IL-6血清水平,改善了肿瘤化疗患者的生活质量;保护骨髓免于化疗毒性作用,增加了患者对化疗的耐受性;MPA良好的临床作用与其抑制肿瘤新生血管作用有关。
Objective To observe the clinical effects of chemotherapy (chemotherapy) plus medroxyprogesterone (MPA) in patients with invasive hydatidiform mole and choriocarcinoma (choriocarcinoma). Methods Twenty-five patients with invasive mole and choriocarcinoma underwent self-control. According to the conventional method, fluorouracil and dactinomycin were used for 8 days. The first course of treatment did not use MPA as the control group. One week before the second course of treatment, 200 mg.d-1 of MPA was used as the experimental group. Long-term group (without MPA), the recent 10 cases of phase III for the recent group (plus MPA). The changes of leukocyte and interleukin-6 (IL-6) in two groups before and after chemotherapy were observed before and after chemotherapy. Transfer the outcome. Results The appetite, nausea, vomiting and oral ulcer in the experimental group were significantly better than those in the control group (P <0.01). There was no significant change in leukocytes before and after chemotherapy in the experimental group (P> 0.05). The level of IL-6 in the experimental group was significantly lower than that in the control group (P <0.01). The number of chemotherapy in the recent group was significantly lower than that in the long-term group. The disappearance time of lung metastasis was shorter than that in the long-term group (P <0.01). Conclusions MPA can reduce the serum IL-6 level, improve the quality of life in patients with chemotherapy, protect bone marrow from chemo-toxicity and increase the patient’s tolerance to chemotherapy. The good clinical effect of MPA and its inhibition of tumor angiogenesis related.